Your browser doesn't support javascript.
loading
Pharmacogenetics in Italy: current landscape and future prospects.
Floris, Matteo; Moschella, Antonino; Alcalay, Myriam; Montella, Annalaura; Tirelli, Matilde; Fontana, Laura; Idda, Maria Laura; Guarnieri, Paolo; Capasso, Mario; Mammì, Corrado; Nicoletti, Paola; Miozzo, Monica.
Afiliação
  • Floris M; Department of Biomedical Sciences, University of Sassari, Sassari, Italy. matteo.floris@gmail.com.
  • Moschella A; Unit of Medical Genetics, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
  • Alcalay M; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milano, Italy.
  • Montella A; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.
  • Tirelli M; CEINGE Biotecnologie Avanzate, Napoli, Italy.
  • Fontana L; Department of Molecular Medicine and Medical Biotechnology (DMMBM), Università degli Studi di Napoli "Federico II", Napoli, Italy.
  • Idda ML; CEINGE Biotecnologie Avanzate, Napoli, Italy.
  • Guarnieri P; Medical Genetics Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Milan, Italy.
  • Capasso M; Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
  • Nicoletti P; 23andMe Inc., Therapeutics, South San Francisco, CA, USA.
  • Miozzo M; CEINGE Biotecnologie Avanzate, Napoli, Italy.
Hum Genomics ; 18(1): 78, 2024 Jul 10.
Article em En | MEDLINE | ID: mdl-38987819
ABSTRACT
Pharmacogenetics investigates sequence of genes that affect drug response, enabling personalized medication. This approach reduces drug-induced adverse reactions and improves clinical effectiveness, making it a crucial consideration for personalized medical care. Numerous guidelines, drawn by global consortia and scientific organizations, codify genotype-driven administration for over 120 active substances. As the scientific community acknowledges the benefits of genotype-tailored therapy over traditionally agnostic drug administration, the push for its implementation into Italian healthcare system is gaining momentum. This evolution is influenced by several factors, including the improved access to patient genotypes, the sequencing costs decrease, the growing of large-scale genetic studies, the rising popularity of direct-to-consumer pharmacogenetic tests, and the continuous improvement of pharmacogenetic guidelines. Since EMA (European Medicines Agency) and AIFA (Italian Medicines Agency) provide genotype information on drug leaflet without clear and explicit clinical indications for gene testing, the regulation of pharmacogenetic testing is a pressing matter in Italy. In this manuscript, we have reviewed how to overcome the obstacles in implementing pharmacogenetic testing in the clinical practice of the Italian healthcare system. Our particular emphasis has been on germline testing, given the absence of well-defined national directives in contrast to somatic pharmacogenetics.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacogenética Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacogenética Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article